Cytosorbents (CTSO) closed at $5.37 on November 12, 2026, up 0.6% from the previous close, on volume of 6,297 shares (30-day average 54,684).
Data as of November 12, 2026.
PRNewswire (Thu, 12-Nov 5:17 PM ET)
Cytosorbents Non-GAAP EPS of -$0.48, revenue of $9.73M misses by $0.18M
Seeking Alpha News (Thu, 12-Nov 4:29 PM ET)
Here are the major earnings after the close Thursday
Seeking Alpha News (Thu, 12-Nov 10:00 AM ET)
Cytosorbents Q3 Earnings Preview
Seeking Alpha News (Wed, 11-Nov 5:35 PM ET)
CytoSorbents to Participate at the 2026 Jefferies Global Healthcare Conference in London
PRNewswire (Mon, 9-Nov 7:00 AM ET)
CytoSorbents to Report Third Quarter 2026 Financial Results and Recent Business Highlights
PRNewswire (Thu, 29-Oct 7:01 AM ET)
PRNewswire (Wed, 30-Sep 7:00 AM ET)
CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement
PRNewswire (Wed, 23-Sep 7:00 AM ET)
CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference
PRNewswire (Thu, 10-Sep 7:00 AM ET)
CytoSorbents Announces Reverse Stock Split
PRNewswire (Thu, 3-Sep 7:00 AM ET)
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
Cytosorbents trades on the NASDAQ stock market under the symbol CTSO.
As of November 13, 2026, CTSO stock price was flat at $5.37 with 1,022 million shares trading.
CTSO has a beta of 1.37, meaning it tends to be more sensitive to market movements. CTSO has a correlation of 0.06 to the broad based SPY ETF.
CTSO has a market cap of $16.92 million. This is considered a Sub-Micro Cap stock.
Last quarter Cytosorbents reported $10 million in Revenue and -$.48 earnings per share. This fell short of revenue expectation by $-187,728 and exceeded earnings estimates by $.42.
In the last 3 years, CTSO traded as high as $43.00 and as low as $2.84.
The top ETF exchange traded funds that CTSO belongs to (by Net Assets): VTI, VXF, MSSM.
CTSO has underperformed the market in the last year with a return of -58.0%, while the SPY ETF gained +11.8%. In the last 3 month period, CTSO fell short of the market, returning -27.4%, while SPY returned -1.8%. However, in the most recent 2 weeks CTSO has outperformed the stock market by returning +22.0%, while SPY returned -1.7%.
CTSO support price is $4.68 and resistance is $6.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTSO shares will trade within this expected range on the day.